| |
CAR-T therapies have transformed treatment for certain hematological malignancies, but their use is limited. Ongoing research seeks to improve safety, efficacy, and lower costs, expanding their application. To learn more, download our white paper. 
|
|
Today’s Big NewsSep 17, 2024 |
|
Different hepatocyte formats have inherent characteristics that make them more suited for certain assays than others so BioIVT outlines the major differences and how they might be useful in your research... Read More >> 
|
|
| By Nick Paul Taylor A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate has hit its primary endpoint, boosting plans to take a second shot at FDA approval. But two more people died after developing interstitial lung disease, and the overall survival data are immature. |
|
|
|
By James Waldron With a trio of biotechs hitting the Nasdaq on Friday, it was easy to miss a smaller-scale public debut from another clinical-stage drug developer on the other side of the ESMO weekend. |
By Nick Paul Taylor Ascendis Pharma has emerged as a potential threat to BioMarin’s Voxzogo, reporting phase 3 growth disorder data that exceeded analyst expectations and positions the biotech to file for approval next year. |
Sponsored by Avacare Clinical Research Network With intricate protocols and shifting regulatory demands, it’s more difficult than ever to find and keep participants, as well as gather reliable data. |
|
Create an optimal path to the clinic that best suits your molecule and critical milestones. We now offer a full suite of integrated drug substance/drug product DNA-to-IND programs to accelerate any molecule type to the clinic. Download our white papers to learn more about our tailored CMC strategies. 
|
|
By Gabrielle Masson Though Alkeus Pharmaceuticals’ oral eye disease asset failed to significantly reduce geographic atrophy (GA) lesion growth, the biotech is citing "clinically meaningful" results and a secondary endpoint win as reasons to pursue further development. |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By James Waldron Five months after Rakovina Therapeutics pivoted toward artificial intelligence, the cancer-focused biotech has joined forces with Variational AI to identify new therapies against DNA-damage response targets. |
By Darren Incorvaia An academic partnership to improve diversity in clinical trials has drafted its first industry team members. Amgen and Merck will help Equitable Breakthroughs in Medicine Development enroll patients in local clinical trials as part of the partnership’s pilot program. |
By Kevin Dunleavy Three months after a jury awarded $260 million to an Oregon woman who claimed that her use of Johnson’s Baby Powder caused her to develop mesothelioma, a state judge has overturned the verdict and granted the company a new trial. |
By Ben Adams New biologics such as GSK's Benlysta and AstraZeneca's Saphnelo, along with off-label drugs, have been the mainstay for systemic lupus erythematosus treatment for many years. However, the landscape may be about to change with the introduction of new medicines and indications from other approved treatments. |
By Fraiser Kansteiner With a hefty investment led by Bain Capital and a new commercial facility on the horizon, growing CDMO Serán Bioscience is looking to bridge the gap between clinic and market for its customers. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report. |
|
|---|
|
|
Whitepaper Unique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
